XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor
Lijia Pan(XinHua Hospital), Zhixiang Wu(XinHua Hospital)
Cited by 29
Related Papers
Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastoma
|Oncotarget|2016|16
P300 Interacted With N-Myc and Regulated Its Protein Stability via Altering Its Post-Translational Modifications in Neuroblastoma
|Molecular & Cellular Proteomics|2023|15